Department of Radiology and Nuclear Medicine, Amsterdam UMC Location AMC, Amsterdam, North Holland, The Netherlands
Department of Biomedical Engineering and Physics, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
J Neurol Neurosurg Psychiatry. 2024 May 14;95(6):515-527. doi: 10.1136/jnnp-2023-331862.
Although CT perfusion (CTP) is often incorporated in acute stroke workflows, it remains largely unclear what the associated costs and health implications are in the long run of CTP-based patient selection for endovascular treatment (EVT) in patients presenting within 6 hours after symptom onset with a large vessel occlusion.
Patients with a large vessel occlusion were included from a Dutch nationwide cohort (n=703) if CTP imaging was performed before EVT within 6 hours after stroke onset. Simulated cost and health effects during 5 and 10 years follow-up were compared between CTP based patient selection for EVT and providing EVT to all patients. Outcome measures were the net monetary benefit at a willingness-to-pay of €80 000 per quality-adjusted life year, incremental cost-effectiveness ratio), difference in costs from a healthcare payer perspective (ΔCosts) and quality-adjusted life years (ΔQALY) per 1000 patients for 1000 model iterations as outcomes.
Compared with treating all patients, CTP-based selection for EVT at the optimised ischaemic core volume (ICV≥110 mL) or core-penumbra mismatch ratio (MMR≤1.4) thresholds resulted in losses of health (median ΔQALYs for ICV≥110 mL: -3.3 (IQR: -5.9 to -1.1), for MMR≤1.4: 0.0 (IQR: -1.3 to 0.0)) with median ΔCosts for ICV≥110 mL of -€348 966 (IQR: -€712 406 to -€51 158) and for MMR≤1.4 of €266 513 (IQR: €229 403 to €380 110)) per 1000 patients. Sensitivity analyses did not yield any scenarios for CTP-based selection of patients for EVT that were cost-effective for improving health, including patients aged ≥80 years CONCLUSION: In EVT-eligible patients presenting within 6 hours after symptom onset, excluding patients based on CTP parameters was not cost-effective and could potentially harm patients.
虽然 CT 灌注(CTP)经常被纳入急性脑卒中工作流程,但在症状发作后 6 小时内进行 CTP 成像以选择适合血管内治疗(EVT)的患者的长期成本和健康影响仍不清楚。
如果在症状发作后 6 小时内进行 EVT 之前进行 CTP 成像,则从荷兰全国队列(n=703)中纳入大血管闭塞患者。比较基于 CTP 的 EVT 患者选择和为所有患者提供 EVT 的 5 年和 10 年随访期间的模拟成本和健康效果。结果测量为每质量调整生命年支付意愿为 80000 欧元时的净货币收益,增量成本效益比(ICER)),从医疗保健支付者角度计算的成本差异(ΔCosts)和每 1000 名患者 1000 次模型迭代的质量调整生命年(ΔQALY)。
与治疗所有患者相比,基于 CTP 的 EVT 选择的最佳缺血核心体积(ICV≥110mL)或核心-半影匹配比(MMR≤1.4)阈值导致健康损失(基于 ICV≥110mL 的中位数ΔQALYs:-3.3(IQR:-5.9 至-1.1),对于 MMR≤1.4:0.0(IQR:-1.3 至 0.0)),对于 ICV≥110mL 的中位数 ΔCosts 为-348966 欧元(IQR:-712406 至-51158 欧元),对于 MMR≤1.4 的为 266513 欧元(IQR:229403 至 380110 欧元))每 1000 名患者。敏感性分析没有产生任何基于 CTP 选择患者进行 EVT 的方案,这些方案在改善健康方面具有成本效益,包括年龄≥80 岁的患者。
在症状发作后 6 小时内符合 EVT 条件的患者中,根据 CTP 参数排除患者没有成本效益,并且可能对患者造成伤害。